Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals ($ENTA) announced an update on their ongoing clinical study. Enanta Targets RSV in Young Children With New Phase 2 Trial Upd...

Enanta’s New RSV Trial in Infants: What Investors Should Watch in ENTA

KeyBanc analyst Bradley Thomas maintained a Buy rating on Central Garden Pet today and set a price target of $50.00. Thomas covers the Consumer Cyc...

Current Quarter	$-0.46	Next Quarter	$-0.43
Current Year	$-1.98	Next Year	$-1.98
QoQ Growth	+6.5%	YoY Growth	+0.0%
3Y EPS CAGR	+13.4%	Target Price	$18.71
Consensus	Buy	Upside	+32.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$14.11	0.00%	227.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$14.11	0%	227.55K
3
4
5
6

ENTA

ENTA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Enanta Pharmaceuticals Inc. Data in Excel

Get Enanta Pharmaceuticals Inc. Data in Excel